Person: TOLUNAY, ŞAHSİNE
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
TOLUNAY
First Name
ŞAHSİNE
Name
30 results
Search Results
Now showing 1 - 10 of 30
Publication Atipical teratoid rhabdoid tumor: Case report and review of the literature(Kare Publ, 2014-01-01) Şahintürk, Kadriye; Özkan, Lütfi; Yazıcı, Zeynep; YAZICI, ZEYNEP; Tolunay, Şahsine; TOLUNAY, ŞAHSİNE; Taşkapılıoğlu, M. Özgür; Demirkaya, Metin; Demiröz Abakay, Candan; DEMİRÖZ ABAKAY, CANDAN; Tıp Fakültesi; Radyasyon Onkolojisi Ana Bilim Dalı; 0000-0001-5472-9065; AAW-5254-2020; AAI-2303-2021; ABB-8161-2020; AAI-1612-2021Atipical teratoid rhabdoid tumor (ATRT) is a rare and highly agressive malign tumor in the early childhood. Mean survival has been reported as 6-11 months. Despite the optimal treatment is unclear surgery, chemotherapy and radiotherapy are the well known treatment options. We would like to report a 4 year old boy who had the diagnosis of ATRT at the temporooccipital region to make a contribution to the literature.Publication NEAT1 Is a novel oncogenic LncRNA and correlated with miR-143 in pediatric oligodendrogliomas(Karger, 2021-03-19) Ak Aksoy, Seçil; Mutlu, Melis; Balçin, Rabia Nur; Taşkapılıoğlu, Mevlut Özgür; Tekin, Çağla; Kaya, Seçkin; Civan, Muhammet Nafi; Kocaeli, Hasan; Bekar, Ahmet; Eser Ocak, Pınar; Çeçener, Gülşah; Egeli, Ünal; Tolunay, Şahsine; Tunca, Berrin; Ak Aksoy, Seçil; Mutlu, Melis; BALÇIN, RABİA NUR; TAŞKAPILIOĞLU, MEVLÜT ÖZGÜR; Tekin, Çağla; KAYA, İSMAİL SEÇKİN; Civan, Muhammet Nafi; KOCAELİ, HASAN; BEKAR, AHMET; Eser Ocak, Pınar; ÇEÇENER, GÜLŞAH; EGELİ, ÜNAL; TOLUNAY, ŞAHSİNE; TUNCA, BERRİN; Tıp Fakültesi; Beyin Cerrahisi Ana Bilim Dalı; 0000-0001-5472-9065; 0000-0002-4256-2250; 0000-0003-0132-9927; 0000-0002-3820-424X; 0000-0001-7904-883X; 0000-0002-1619-6680; ADM-8457-2022; FPB-0403-2022; GXV-3107-2022; AAW-5254-2020; GDC-6329-2022; JGS-1849-2023; HKP-0793-2023; FDK-3229-2022; CGB-7869-2022; AAI-2073-2021; AAP-9988-2020; AAH-1420-2021; AAI-1612-2021; ABI-6078-2020Introduction: The noncoding RNAs (ncRNAs) play a role in biological processes of various cancers including gliomas. The majority of these transcripts are uniquely expressed in differentiated tissues or specific glioma types. Pediatric oligodendroglioma (POG) is a rare subtype of diffuse glioma and accounts for <1% of pediatric brain tumors. Because histologically POG resembles adult OG, the same treatment is applied as adults. However, the significance in predicting outcomes in POG patients is unclear. In this study, we aimed to investigate the prognostic significance of expression -profiles of microRNA (miRNA) and long noncoding RNA -(LncRNA) in POGs. Methods: We investigated the levels of 13 known miRNAs and 6 LncRNAs in tumor samples from 9 patients with primary POG by using RT-PCR and analyzed their association with outcomes. Results: The expression levels of miR-21, miR-106a, miR-10b, and LncRNA NEAT1 were higher, and the expression level of miR-143 was lower in POG tissues compared with normal brain tissues (p = 0.006, p = 0.032, p = 0.034, p = 0.002, and p = 0.001, respectively). High levels of NEAT1 and low expression of miR-143 were associated with decreased probability of short disease-free survival (p = 0.018 and p = 0.022, respectively). Discussion: NEAT1 and miR-143 levels could serve as reciprocal prognostic predictors of disease progression in patients with POG. New treatment models to regulate the expression levels of NEAT1 and miR-143 will bring a new approach to the therapy of POG.Publication A case of extensive ductal carcinoma in situ and sclerosing adenosis with metastasis on sentinel lymph node(Sage Publications Ltd, 2019-08-28) NARTER, SELİN; HASDEMİR, SEÇİL; Hasdemir, Seçil; Gökgöz, Şehsuvar; GÖKGÖZ, MUSTAFA ŞEHSUVAR; Tolunay, Şahsine; TOLUNAY, ŞAHSİNE; Tıp Fakültesi; Patoloji Ana Bilim Dalı; 0000-0003-1769-7484; AAI-1612-2021Introduction: Sclerosing adenosis is a form of adenosis characterized by lobulocentric architecture, glandular and stromal proliferation in which the stromal component compresses and distorts the glandular structures. Atypical epithelial proliferations such as atypical lobular hyperplasia, lobular carcinoma in situ, and ductal carcinoma in situ may accompany areas of sclerosing adenosis. We present a case of ductal carcinoma in situ and sclerosing adenosis with metastatic carcinoma on sentinel lymph node. Case description: A 40-year-old woman presented with a palpable mass in her left breast. Radiologic studies showed a lesion suggesting malignancy in the left breast and atypical lymph node in the left axillary region. Left lumpectomy and sentinel lymph node biopsy was performed. Histopathologic examination revealed lobulocentric lesions with glandular proliferation and hyalinizing stroma in between. Foci of high-grade cribriform and solid type ductal carcinoma in situ were observed. Sentinel lymph node biopsy showed micrometastasis in one lymph node section. Based on these findings, the patient was diagnosed with high-grade ductal carcinoma in situ with sclerosing adenosis. However, the presence of micrometastasis in the lymph node suggested occult invasion that we were not able to detect. Conclusion: Ductal carcinoma in situ with sclerosing adenosis can mimic invasive carcinoma both radiologically and histologically. It should be kept in mind that there may be occult invasive carcinoma in patients with ductal carcinoma in situ whether the lesion is accompanied by sclerosing adenosis or not. Multiple sections and immunohistochemical studies can be of help.Publication The immunohistochemical expression of c-met is an independent predictor of survival in patients with glioblastoma multiforme(Springer International Publishing Ag, 2014-02-01) Ölmez, O. F.; Çubukçu, E.; ÇUBUKÇU, ERDEM; Evrensel, T.; EVRENSEL, TÜRKKAN; Kurt, M.; Avcı, N.; Tolunay, S.; TOLUNAY, ŞAHSİNE; Bekar, Ahmet; BEKAR, AHMET; Deligönül, Adem; DELİGÖNÜL, ADEM; Hartavi, M.; Alkış, N.; Manavoğlu, O.; Tıp Fakültesi; Onkoloji Ana Bilim Dalı; ABX-9081-2022; AAJ-1027-2021; AAA-3961-2020; AAI-1612-2021Because the outcome of glioblastoma multiforme (GBM) remains dismal, there is an urgent need for a better molecular characterization of this malignancy. The aim of this prospective study was to investigate the prognostic impact of the expression of c-mesenchymal-epithelial transition (c-Met) a receptor tyrosine kinase implicated in expression growth, survival, motility/migration, and invasion in GMB patients managed according to the established diagnostic and therapeutic protocols.Between May 2003 and March 2011, a total of 69 patients (33 males and 36 females; mean age: 52.2 +/- A 12.9 years, age range: 23-81 years) referred to our Department for the surgical removal of GBM were evaluated immunohistochemically for c-Met expression. Progression-free survival (PFS) and overall survival (OS) served as the main outcome measures.Compared with c-Met- subjects (n = 38), c-Met+ subjects (n = 31) had both a significantly lower OS (15.3 +/- A 2.3 vs. 22.6 +/- A 2.5 months, respectively, p < 0.01) and PFS (12.3 +/- A 2.1 vs. 19.1 +/- A 2.6 months, respectively, p < 0.05). After allowance for potential confounders, multivariate Cox regression analysis identified c-Met+ as an independent predictor of both OS (hazard ratio = 1.7; 95 % confidence interval = 1.2-1.9, p < 0.01) and PFS (hazard ratio = 1.6; 95 % confidence interval = 1.1-2.3, p < 0.05).Our findings suggest that c-Met immunohistochemical expression is an independent predictor of outcomes in patients with GBM treated by standard of care.Publication Diabetes mellitus-mediated MALAT1 expression induces glioblastoma aggressiveness(Turkish Neurosurgical Soc, 2023-01-01) Kocaeli, Aysen Akkurt; Aksoy, Seçil A. K.; Erçelik, Melis; Tezcan, Gülçin; Tekin, Çağla; Kocaeli, Hasan; Bekar, Ahmet; Taşkapılıoğlu, Mevlüt Özgür; Tolunay, Şahsine; Tunca, Berrin; AKSOY, SEÇİL; Erçelik, Melis; TEZCAN, GÜLÇİN; Tekin, Çağla; KOCAELİ, HASAN; BEKAR, AHMET; TAŞKAPILIOĞLU, MEVLÜT ÖZGÜR; TOLUNAY, ŞAHSİNE; TUNCA, BERRİN; Tıp Fakültesi; Tıbbi Biyoloji Ana Bilim Dalı; 0000-0002-3760-9755; ADM-8457-2022; EUG-3329-2022; JJL-1176-2023; GDC-6329-2022; FDK-3229-2022; JWS-5881-2024; IRO-2619-2023; AAI-1612-2021; JXJ-7901-2024AIM: To describe the role of metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) in glioblastoma (GB) progression in patients concurrently diagnosed with diabetes mellitus (DM).MATERIAL and METHODS: Formalin-fixed paraffin-embedded (FFPE) tumor samples of 47 patients diagnosed with GB only and 13 patients diagnosed with GB and DM (GB-DM) were enrolled in this study. Data for p53 and Ki67 immunohistochemical staining of the tumors and blood HbA1c levels of patients with DM were retrospectively collected. MALAT1 expression was assessed using quantitative real-time polymerase chain reaction.RESULTS: The coexistence of GB and DM induced the nuclear expression of p53 and Ki67 compared with GB only. MALAT1 expression was higher in GB-DM tumors than in GB only tumors. The expression of MALAT1 and HbA1c levels were positively correlated. Additionally, MALAT1 was positively correlated with tumoral p53 and Ki67. The disease-free survival of patients with GB-DM with high MALAT1 expression was shorter than that of those diagnosed with GB only and with a lower MALAT1 expression.CONCLUSION: Our findings suggest that one of the mechanisms of the facilitating effect of DM on GB tumor aggressiveness is via MALAT1 expression.Publication Primary pulmonary amyloidosis associated with multiple myeloma(Turkish Assoc Tuberculosis & Thorax, 2006-01-01) Ege, Ercüment; URSAVAŞ, AHMET; Uzaslan, Esra; UZASLAN, AYŞE ESRA; Ursavaş, Ahmet; Güçlü, Metin; Özkalemkaş, Fahir; ÖZKALEMKAŞ, FAHİR; Tolunay, Şahsine; TOLUNAY, ŞAHSİNE; Tıp Fakültesi; Göğüs Hastalıkları Ana Bilim Dalı; 0000-0001-5082-9894; ABI-4847-2020; AAI-1612-2021; AAG-8495-2021; AAI-3169-2021; AAI-1004-2021Amyloidosis is a syndrome characterized by the deposition of an insoluble proteinaceous material in the extracellular matrix of one or several organs. Respiratory tract involvement with amyloid is rare and deposition of lower respiratory tract has been recognized in a variety of situations with different presentations. Primary idiopathic amyloidosis may be a diagnostic problem because of its low incidence and its variable manifestations. We report herein a case with multiple myeloma presenting diffuse interstitial infiltration, in which pulmonary AL type amyloidosis was diagnosed through transbronchial lung biopsy.Publication Hemorrhagic presentation of previously silent brain tumors(Elsevier Espana Slu, 2023-07-03) Türkkan, Alper; Khezri, Marzieh Karimi; Eser, Pınar; Kuytu, Turgut; Tolunay, Şahsine; Bekar, Ahmet; TOLUNAY, ŞAHSİNE; BEKAR, AHMET; Eser, Pınar; Tıp Fakültesi; Patoloji Ana Bilim Dalı; 0000-0003-0132-9927; AAI-2073-2021; CGB-7869-2022; AAI-1612-2021Introduction and objectives: Acute presentation with intracranial hemorrhage owing to a previously silent brain tumor (BT) is rare. Although any BT can bleed, the frequency and type of bleeding varies across tumor types.Materials and methods: We aimed to retrospectively review our experience with 55 patients with BTs presenting with ICH.Results: Signs of increased intracranial pressure were the most common symptoms. The temporal lobe was the most common lesion site (n = 22). Hemorrhages were mainly confined to the tumor margins (HCTs) (n = 34). Extensive intraparenchymal hemorrhages (EIHs) were mainly associated with moderately/severely decreased levels of consciousness (LOCs) (n = 15/16). High-grade glioma (HGGT) (n = 25) was the leading pathological diagnosis followed by metastasis (MBT) (n = 16/55). The hemorrhage type was associated with the pathological diagnosis of the tumor. Patients with HGGT (n = 19/25) and MBT (n = 9/16) mainly presented with HCTs, whereas low-grade gliomas (LGGT) primarily caused EIHs (n = 6/7).Conclusions: Hemorrhagic presentation is a rare occurrence in BTs. Among all, MBT and HGGT are responsible for majority of the cases. Importantly, despite their relatively benig ncharacteristics, LGGTs mainly result in extensive parenchymal destruction once they bleed. Maximum surgical resection of hemorrhagic BTs and decompression of the affected brain regions followed by histological confirmation of the diagnosis should be the main goals of treatment in cases with hemorrhagic BTs.(c) 2022 Published by Elsevier Espana, S.L.U. on behalf of Sociedad Espanola deNeurocirug ' ia.Publication General characteristics of male breast cancer patients in Bursa region(Aves, 2012-07-01) Avcı, Nilüfer; Balcı, Mehmet Ali; Esen, İrfan; Tandoğan, Gülen; Merter, Mustafa; Çubukcu, Erdem; Ölmez, Fatih; Coşkun, Belkıs Nihan; Hartavi, Mustafa; Tolunay, Şahsine; Avcı, Nilüfer; Balcı, Mehmet Ali; Esen, İrfan; Tandoğan, Gülen; Merter, Mustafa; ÇUBUKÇU, ERDEM; Ölmez, Fatih; COŞKUN, BELKIS NİHAN; Hartavi, Mustafa; TOLUNAY, ŞAHSİNE; Tıp Fakültesi; Medikal Onkoloji Ana Bilim Dalı; 0000-0003-1465-7153; AAI-1612-2021; ABD-7124-2020; AAG-7155-2021; ABI-4413-2020; CCT-7946-2022; DYT-8587-2022; DFP-9003-2022; JGT-4101-2023; JGV-7746-2023; CUI-5353-2022Introduction: Male breast cancer constitutes less than 1% of all cases of breast cancer. In this study, we analyzed clinical and pathological features of male breast cancer cases, which had been followed up and treated at our institution.Material and Method: The data regarding the main clinicopathological features of the male breast cancer patients were retrieved from the patients' records retrospectively.Results: A total of 16 patients were included in the analysis with a median age of 60 (41-75). The most common cell type was infiltrating ductal carcinoma, comprising 81.3 % of all cases. Most patients were staged as locally advanced (50% - stage 3) at the time of diagnosis. Estrogen and/or progesterone receptor positivity were found in 13 patients (81.3%). HER2 status could be examined in 9 patients, and 4 patients (25%) found to be positive for HER2 overexpression. Overall survival was 3(1-12) years and disease-free survival was 2 (1-8) years.Discussion: Despite the increasing knowledge about breast cancer in women, little is known in case of male breast cancer management. Therefore, there is a strong need to perform randomized studies for the treatment of male breast cancer.Publication Metaplastic breast cancer and EGFR expression(Derman Medical Publ, 2015-09-01) Avcı, Nilüfer; Ulaş, Arife; Ordu, Çetin; Aydın, Taner; Tolunay, Şahsine; Oven, Bala Başak Ustaalioğlu; Kurt, Ender; Evrensel, Türkkan; Avcı, Nilüfer; Aydın, Taner; TOLUNAY, ŞAHSİNE; Kurt, Ender; EVRENSEL, TÜRKKAN; Tıp Fakültesi; İç Hastalıkları Ana Bilim Dalı; 0000-0002-9732-5340 ; CCT-7946-2022; CEK-5895-2022; AAI-1612-2021; DAS-3088-2022; AAJ-1027-2021Aim: Metaplastic breast cancer has poor prognosis and is usually triple negative. Although it is morphologically more heterogeneous than triple negative breast cancers, expression profile is more homogeneous. In this study, we investigated our metaplastic breast cancer cases regarding their pathology and clinical characteristics. Material and Method: 16 metaplastic breast cancer cases from four different center were included in the study. Pathology and clinical characteristics of the cases were evaluated retrospectively. Results: All the cases are female and median age is 48 (39-45). Tumor is commonly localized to the outer quadrant and mean diameter of the mass is 37.5 (15-100) mm. Tumor diameter is <= 20 mm in 3 (15.8%), >20-<= 50 mm in 11 (57.9%) and >50 mm in 3 (10.51%) of the cases. Only 4 (16.1%) patients have axillary lymph node involvement. When considering histological subtypes, five of the cases has squamous cell, five of them has spindle cell, one of them has mucoepidermoid, and in five cases the subtype was not identified. Considering hormone receptor status ER and PR was negative in 78.9%, 63.2% respectively. HER2 protein expression was positive by immunohistochemical staining in 1 (5.3%) case. CK5/6 and CK17 was both positive in 7 (36.8%) cases. EGFR expression was positive in 4 (21.1%) cases, was negative in 5 (26.3%) cases and not identified in 7 (36.8%) cases. Three of the cases were offered neoadjuvant chemotherapy. As neoadjuvant chemotherapy, anthracycline and taxane combination (n:2 TAC, n:1 AC-paclitaxel) was preferred. Mean follow-up was 41 months. Mean survival was 42.4 months in EGFR negative patients and 47.5 months in EGFR positive patients. This difference was not statistically significant. During follow-up 3 cases had recurrence. Discussion: EGFR expression is seen in metaplastic breast cancer. Although EGFR expression is related to poor prognosis, it is not a predictive marker. Therefore, predictive molecular markers are required for new approaches in treatment.Publication Gliosarcomas: Analysis of 9 cases treated with radiotherapy(Elsevier Ireland Ltd, 2008-09-01) Edincik, C.; Sarıhan, S.; Yıldırım, S.; Kurt, M.; Çetintaş, S.; Doğan, S.; Tolunay, S.; Edincik, C.; SARIHAN, SÜREYYA; Yıldırım, S.; KURT, MERAL; ÇETİNTAŞ, SİBEL; Doğan, Selda; TOLUNAY, ŞAHSİNE; Tıp Fakültesi; Beyin Cerrahisi Ana Bilim Dalı; 0000-0003-4816-5798; 0000-0003-2589-8585; AAA-7047-2020; AAH-4970-2021; I-7575-2015; AAI-1612-2021; AAA-3961-2020; EWI-7826-2022; EFX-2827-2022
- «
- 1 (current)
- 2
- 3
- »